Mark T. Gladwin, MD
Professor of Medicine

Dr. Gladwin is the Jack D. Myers Professor and Chairman of the Department of Medicine, and a member of the of the Cellular and Molecular Pathology Graduate Training Program.

Office Location:
1218 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Contact Information:
Office Telephone: 412-648-9641
Lab Telephone: 412-624-0465


  • MD - University of Miami, 1991

Clinical Expertise

He has served as a principal or associate investigator on more than 50 human subjects protocols and holds 10 FDA INDs for the use of investigational therapeutic medications, including nitrite, carbon monoxide, L-NMMA, and sildenafil.

Research Interests

Dr. Gladwin's research activities have led to four major discoveries:
  1. The discovery that the nitrite anion is a circulating storage pool for NO bioactivity (Gladwin, et al. PNAS 2000) that regulates hypoxic vasodilation (Cosby Nature Medicine 2003) and the cellular resilience to low oxygen and ischemia (Duranski JCI 2005).
  2. The discovery of a novel physiological function for hemoglobin as an electronically and allosterically-regulated nitrite reductase (Cosby, et al. Nature Medicine 2003; Huang et al. JCI 2005).
  3. The characterization of a novel mechanism of disease, hemolysis-associated endothelial dysfunction (Reiter, et al. Nature Medicine 2002; Morris et al. JAMA 2005; Minneci et al. JCI 2005; Rother et al. JAMA 2005).
  4. The mechanistic, clinical, and epidemiological description of a human disease syndrome, hemolysis-associated pulmonary hypertension (Gladwin, et al. NEJM 2004).


  • American Board of Internal Medicine Certifying Examination, 1994
  • Recertified Diplomat, American Board of Internal Medicine valid through 2018
  • Diplomat in Pulmonary Disease, American Board of Pulmonary Medicine 1998-2008
  • Recertified in Pulmonary Disease, American Board of Pulmonary Medicine 2008-2018
  • Diplomat in Critical Care Medicine, American Board of Critical Care Medicine 1999-2009
  • Recertified in Critical Care Medicine, American Board of Pulmonary Medicine 2009-2019
  • Medical Licenses:
    • Pennsylvania # MD434600 - active
    • Maryland #D0052428 - active
    • Oregon #MD17824 (expired in good standing 12/31/97)
    • Washington #ML20005389 (expired in good standing 7/31/97)
    • District of Columbia #MD30661 (expired in good standing 12/31/05)
  • Advanced Trauma Life Support, 1997
  • Advanced Cardiac Life Support, 1999 - Present


Pulmonary Hypertension and Sickle Cell Disease

Selected Publications

View Dr. Gladwin's publications on PubMed

  1. Gladwin MT, Shelhamer JH, Schechter AN, Pease-Fye ME, Waclawiw MA, Panza JA, Ognibene FP, Cannon RO III (2000) Role of circulating nitrite and S-nitrosohemoglobin in regulation of regional blood flow in humans. Proc Natl Acad Sci USA. 10;97(21):11482-7.
  2. Reiter CD, Wang X, Tanus-Santos JE, Hogg N, Cannon RO 3rd, Schechter AN, Gladwin MT (2002) Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell-disease. 2002 Dec 8(12):1383-9.
  3. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO 3rd, Gladwin MT (2003) Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med. 9(12):1498-505.
  4. Hunter CJ, Dejam A, Blood AB, Shields H, Kim-Shapiro DB, Machado RF, Tarekegn S, Mulla N, Hooper AO, Schechter AN, Power GG, Gladwin MT (2004) Inhaled nebulized nitrite is a hypoxia-sensitive NO-dependent selective pulmonary vasodilator. Nat Med. 10(10):1122-7.
  5. Gladwin MT, Sachdev V, Jison ML, Shizukuda Y, Plehn JF, Minter K, Brown B, Coles WA, Nichols JS, Ernst I, Hunter LA, Blackwelder W, Schechter AN, Rodgers GP, Castro O, Ognibene FP (2004) Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 350(9):886-95.
  6. Huang Z, Shiva S, Kim-Shapiro DB, Patel RP, Ringwood LA, Irby CE, Huang KT, Ho C, Schechter AN, Hogg N, Gladwin MT (2005) Enzymatic function of hemoglobin as a nitrite reductase that produces NO under allosteric control. J Clin Invest. 115(8):2099-107.
  7. Shiva S, Sack MN, Greer JJ, Duranski M, Ringwood LA, Burwell L, Wang X, MacArthur PH, Shoja A, Raghavachari N, Calvert JW, Brookes PS, Lefer DJ, and Gladwin MT. (2007) Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer. J Exp Med. 204(9):2089-102.
  8. Basu S, Grubina R, Huang J, Conradie J, Huang Z, Jeffers A, Jiang A, He X, Azarov I, Seibert R, Mehta A, Patel R, King SB, Hogg N, Ghosh A, Gladwin MT, Kim-Shapiro DB. Catalytic generation of N2O3 by the concerted nitrite reductase and anhydrase activity of hemoglobin. Nat Chem Biol. 2007 Dec;3(12):785-94
  9. Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, Gladwin MT (2011) Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation.124(4):465-76.
  10. Azarov I, Wang L, Rose JJ, Xu Q, Huang XN, Belanger A, Wang Y, Guo L, Liu C, Ucer KB, McTiernan CF, O'Donnell CP, Shiva S, Tejero J, Kim-Shapiro DB, Gladwin MT (2016) Five-coordinate H64Q neuroglobin as a ligand-trap antidote for carbon monoxide poisoning. Sci Transl Med. 8(368):368ra173